Lido Advisors LLC Acquires 2,060 Shares of AbbVie Inc (ABBV)

Share on StockTwits

Lido Advisors LLC boosted its holdings in shares of AbbVie Inc (NYSE:ABBV) by 8.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,668 shares of the company’s stock after buying an additional 2,060 shares during the period. Lido Advisors LLC’s holdings in AbbVie were worth $2,458,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ABBV. Oregon Public Employees Retirement Fund boosted its stake in AbbVie by 4,385.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 15,195,586 shares of the company’s stock worth $165,000 after buying an additional 14,856,786 shares in the last quarter. Matthew Goff Investment Advisor LLC boosted its stake in shares of AbbVie by 9,165.1% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 2,226,305 shares of the company’s stock valued at $24,029,000 after purchasing an additional 2,202,276 shares in the last quarter. Federated Investors Inc. PA boosted its stake in shares of AbbVie by 66.8% in the 3rd quarter. Federated Investors Inc. PA now owns 3,669,632 shares of the company’s stock valued at $347,074,000 after purchasing an additional 1,469,718 shares in the last quarter. Rehmann Capital Advisory Group boosted its stake in shares of AbbVie by 8,776.1% in the 3rd quarter. Rehmann Capital Advisory Group now owns 1,318,197 shares of the company’s stock valued at $13,937,000 after purchasing an additional 1,303,346 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. acquired a new stake in shares of AbbVie in the 4th quarter valued at $97,947,000. Hedge funds and other institutional investors own 70.53% of the company’s stock.

ABBV has been the topic of several recent analyst reports. Argus downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Monday, March 25th. Credit Suisse Group set a $78.00 target price on shares of AbbVie and gave the company a “sell” rating in a research note on Friday, April 26th. ValuEngine downgraded shares of AbbVie from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. BMO Capital Markets upgraded shares of AbbVie from an “underperform” rating to a “market perform” rating and boosted their target price for the company from $71.00 to $79.00 in a research note on Sunday, April 28th. Finally, UBS Group restated a “neutral” rating and issued a $91.00 target price (down previously from $97.00) on shares of AbbVie in a research note on Wednesday, January 23rd. Six research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. AbbVie presently has an average rating of “Hold” and a consensus target price of $94.95.

In related news, Vice Chairman Laura J. Schumacher sold 25,000 shares of AbbVie stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $80.00, for a total value of $2,000,000.00. Following the completion of the transaction, the insider now directly owns 139,838 shares of the company’s stock, valued at $11,187,040. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Brian L. Durkin sold 475 shares of AbbVie stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $79.69, for a total value of $37,852.75. Following the completion of the transaction, the vice president now directly owns 9,121 shares of the company’s stock, valued at $726,852.49. The disclosure for this sale can be found here. Insiders sold 41,272 shares of company stock valued at $3,286,290 over the last ninety days. 0.08% of the stock is currently owned by company insiders.

AbbVie stock opened at $79.46 on Friday. AbbVie Inc has a 12-month low of $75.62 and a 12-month high of $107.25. The stock has a market capitalization of $117.47 billion, a P/E ratio of 10.05, a price-to-earnings-growth ratio of 1.62 and a beta of 1.14.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Thursday, April 25th. The company reported $2.14 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.06 by $0.08. AbbVie had a negative return on equity of 221.09% and a net margin of 16.42%. The business had revenue of $7.83 billion during the quarter, compared to analysts’ expectations of $7.81 billion. During the same period in the previous year, the business posted $1.87 earnings per share. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. On average, research analysts predict that AbbVie Inc will post 8.83 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 15th. Investors of record on Monday, April 15th were issued a $1.07 dividend. The ex-dividend date of this dividend was Friday, April 12th. This represents a $4.28 dividend on an annualized basis and a dividend yield of 5.39%. AbbVie’s dividend payout ratio is 54.11%.

COPYRIGHT VIOLATION NOTICE: This report was posted by Week Herald and is the property of of Week Herald. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://weekherald.com/2019/05/19/lido-advisors-llc-acquires-2060-shares-of-abbvie-inc-abbv.html.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Recommended Story: Should You Consider an Index Fund?

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.